LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
TOKYO, May 26, 2023 – (JCN Newswire) – Eisai and Merck & Co., Inc., Rahway,…